18:13 , Dec 8, 2017 |  BioCentury  |  Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

BioMarin, Serono deal

BioMarin will regain rights to phenylketonuria (PKU) treatments Kuvan sapropterin dihydrochloride and pegvaliase ( BMN 165 ) from the Merck Serono S.A. unit of Merck KGaA (Xetra:MRK, Darmstadt, Germany). Merck held ex-U.S. and Japan rights...
00:58 , Oct 2, 2015 |  BC Extra  |  Company News

BioMarin buys back PKU franchise from Merck Serono

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) regained rights to phenylketonuria (PKU) treatments Kuvan sapropterin dihydrochloride and pegvaliase ( BMN 165 ) from the Merck Serono S.A. unit of Merck KGaA (Xetra:MRK). Merck held ex-U.S. and Japan rights...
00:53 , Aug 4, 2015 |  BC Extra  |  Company News

BioMarin revenues rise as it awaits DMD meeting

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported earnings and said it is planning an early 2016 launch for drisapersen , its therapy for Duchenne muscular dystrophy amenable to exon 51 skipping. The antisense oligoribonucleotide that induces exon...
01:50 , Mar 28, 2015 |  BC Extra  |  Top Story

BioMarin rises on takeout rumors

Rare disease company BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) jumped $13.23 (11%) to $128.78 on Friday, ending the day with a market cap of $20.5 billion, amid rumors that Shire plc (LSE:SHP; NASDAQ:SHPG) has approached it with...
08:00 , Dec 8, 2014 |  BioCentury  |  Strategy

BioMarin bulks up

Five years after discussing a licensing deal with Prosensa Holding N.V. , BioMarin Pharmaceutical Inc. decided to acquire the Duchenne muscular dystrophy play to get what could become the California company's largest drug. BioMarin believes...
07:00 , Oct 27, 2014 |  BioCentury  |  Finance

Waiting for better times

Poised to complete the fourth-largest European biotech IPO since 2008, the road show for Molecular Partners AG had the poor luck of coinciding with the largest one-week drop in the broader capital markets since the...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
07:00 , Jun 16, 2014 |  BioCentury  |  Regulation

Signal crossing

FDA 's workshop on neurological symptoms in inborn errors of metabolism revealed conflicts between how caregivers would like symptoms assessed and what drug companies need to test to get therapies approved. The June 10 workshop...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Pulling off the AZ gambit

Pfizer Inc. (NYSE:PFE) still has room to maneuver if it is really intent on using its bid for AstraZeneca plc (LSE:AZN; NYSE:AZN) to relocate in the more tax-friendly U.K. The trick is to provide enough...